Articles related to DRUG DEVELOPMENT

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.